Announcement PDF ASX Announcement WA Government Sponsorship for BIO Korea 2023 SYDNEY Australia, 8 May 2023: Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the Company developing a new class of Synthetic Anti-infectives, is pleased to announce it has received sponsorship from the West Australian Government to attend BIO Korea 2023. The Company was selected as one of three West Australian companies to attend BIO Korea 2023 and participate in the Australian Biotech Mission. The sponsorship includes registration and participation fees, one-on-one meetings and VIP participation in networking events. The conference will be held on May 10-12, 2023 at COEX in Seoul, South Korea. In 2022, the conference had companies and attendees from over 50 countries and 22,401 on-site visitors. Attendees include the world’s leading biotech companies, investors, executives, business experts and researchers. The event will provide the Company with important business opportunities including partnership opportunities, government networking, clinical research collaborations, regulatory guidance and clinical trial expansion. This announcement has been approved for release by Recce Pharmaceuticals Board. About Recce Pharmaceuticals Ltd Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a new class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date. The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world’s only synthetic polymer and sepsis drug candidate in development. RECCE® 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy. Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce’s antiinfective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.